Bulletin from Bactiguard Holding AB’s (publ) Annual General Meeting
At Bactiguard Holding AB’s (publ) Annual General Meeting (AGM) on 29 April 2022, the following resolutions were made:
The AGM adopted the income statements and balance sheets for 2021 and decided that no dividend for the financial year 2021 will be paid. Retained earnings and the company's result for the year will be carried forward.
The Board of Directors and CEOs were discharged from liability for their administration of the company for the financial year 2021.
The AGM resolved that the remuneration until the next AGM shall be paid in an amount of SEK 750 000 respectively to the Chairman of the Board and the deputy Chairman and SEK 400 000 to each of the other Directors. No additional remuneration shall be paid for committee work.
Thomas von Koch, Christian Kinch, Anna Martling and Jan Ståhlberg were re-elected as board members and Magdalena Persson was elected as new member of the Board. Thomas von Koch was re-elected Chairman of the Board and Christian Kinch was re-elected deputy Chairman of the Board.
Deloitte AB was re-elected by the AGM as auditors for the period until the close of the next AGM and it was resolved that remuneration to the auditors shall be paid according to approved invoices.
The AGM adopted the remuneration report, proposed by the Board.
The AGM resolved, in accordance with the Board's proposal, on the authorization for the Board to decide on a new issue of shares, warrants and / or convertibles.
Due to the ongoing pandemic the AGM was held with participation only by postal voting, without physical presence.
For further information, please contact:
Gabriella Björknert Caracciolo, CFO and deputy CEO, mobile +46 72 141 62 49
About Bactiguard
Bactiguard is a Swedish medical device company with a mission to save lives. To achieve this mission, we develop and supply infection prevention solutions which reduce the risk of infections and the use of antibiotics. This way, we save significant costs for healthcare and the society at large.
The Bactiguard technology is based on a thin noble metal alloy coating that prevents bacterial adhesion and biofilm formation on medical devices. Bactiguard offers the technology through licence agreements and our BIP (Bactiguard Infection Protection) portfolio of products. Urinary catheters with the Bactiguard technology are market leading in the USA and Japan through our licensing partner BD, and in 2021 orthopaedic trauma implants, ZNN Bactiguard, were launched by Zimmer Biomet. Bactiguard's product portfolio also includes a non-alcoholic product line for wound care and disinfection. It effectively kills microbes while being biocompatible and tissue friendly.
Bactiguard is in a strong expansion phase in the markets in Europe, China, India, the Middle East and Southeast Asia through our own product portfolio and by establishing licensing deals in new therapy areas. Bactiguard has about 210 employees around the world. Its headquarters and one of three production facilities are located in Stockholm, the other two in Malaysia. Bactiguard is listed on Nasdaq Stockholm.
Read more about Bactiguard www.bactiguard.com